Introduction
Inherited germline mutations in the tumor suppressor gene BRCA2 are associated with increased susceptibility to cancers of the breast, ovaries, pancreas and prostate (1, 2) . Of note, BRCA2 mutations are also associated with considerably reduced survival among prostate cancer patients (3, 4) but little is known about the biological role of the BRCA2 protein in prostate cancer progression.
There is strong evidence that the BRCA2 protein has an important function in the cell nucleus, promoting DNA repair by homologous recombination (5) (6) (7) (8) . Highly conserved functional domains have been identified at both the C-and N-terminus of the protein (9) , but BRCA2 is exceptionally large and lacks substantial sequence similarity to other known proteins so much remains to be understood. Several functions have been proposed other than the DNA repair activity (10) , most of which are likely to be exerted in the nucleus. C-terminal truncations have been found to render the BRCA2 protein unable to translocate to the nucleus, causing it to accumulate in the cytoplasm (8, 11) . Though the BRCA2 protein has no currently known role at the cell membrane, the BRCA1 protein which similarly maintains genomic stability in the nucleus has recently been implicated in cancer spread and motility through activity at the cell membrane (12) .
Although BRCA2 protein levels are presumably diminished in carriers of deleterious inherited mutations in the BRCA2 gene, it has not been previously studied whether protein levels in prostate cancer cells of newly diagnosed non-carriers or individuals from the general population predict progression of disease. However, one study reported a considerably lower percentage of cores with nuclear BRCA2 protein expression in prostate cancer cells as compared to cells from normal prostate (13) .
In a cohort of men with initially untreated prostate cancer and unknown BRCA2 mutation status, we undertook a study to assess whether BRCA2 protein expression in tumor tissue is a biomarker for prostate cancer progression. We hypothesized that diminished levels of BRCA2 protein expression in prostate cancer cells at the time of diagnosis would be associated with unfavorable disease outcome. We also explored whether positive staining, using N-and C-terminal BRCA2 antibodies, in the cell membrane, cytoplasm or nucleus, would be predictive of prostate cancer grade and lethality. We made the a priori decision to focus on early lethal prostate cancer and defined case status as death from prostate cancer within 5 years of diagnosis.
Materials and methods

Patient population
The population-based Swedish Watchful Waiting cohort consists of men with localized prostate cancer, diagnosed in the southeast of Sweden at the University Hospital in Örebro from 1977 to 1994 or at the South East Health Care Regions of Sweden from 1987 to 1998. Details of this cohort have been published previously (14, 15) . The patients included in the cohort were diagnosed incidentally following transurethral resection of the prostate (TURP) performed for symptomatic benign prostatic hyperplasia. Eligible patients were identified through population-based prostate cancer databases. In accordance with prevailing standards, patients were followed expectantly. No prostate-specific antigen screening programs were in place during this period. All patients had a diagnosis of clinical stage T1, Mx and Nx and were followed prospectively for prostate cancer metastasis and death through May 2006 (16) . All patients with prostate cancer were recruited through an informed consent process at the respective institutions and the study is compliant with Karolinska and Örebro ethical committees.
For this nested case-control study, cases included all men who died from prostate cancer within 5 years of diagnosis (N = 71). They were a subgroup of 141 cases with lethal prostate cancer that occurred 4 months to 19 years after diagnosis based on follow-up through 2006. Indolent controls were all men who lived at least 7 years after diagnosis without evidence of metastatic disease by the end of follow-up (N = 165).
BRCA2 immunohistochemistry
Archival TURP tissue specimens were available for these patients, and H&E slides underwent standardized histopathologic review. We constructed tumor tissue microarrays (TMAs) by sampling two cores from high-density areas with at least 90% tumor cells. The dominant prostate cancer focus or foci were identified. Sections (5 μm) of each of six TMA blocks were cut and mounted onto charged slides. Paraffin sections were deparaffinized with xylene, rehydrated through a series of graded alcohols, and then washed in phosphate-buffered saline. Two different primary BRCA2 antibodies were used on individual TMA sections at a dilution of 1:100 applied overnight at 4°C. The BRCA2 antibodies were: (i) a monoclonal antibody (R&D Systems, Minneapolis, MN) against amino acids 1-200 of human BRCA2 in the N-terminal domain and (ii) a rabbit polyclonal BRCA2 antibody (Calbiochem, San Diego, CA) against amino acids 3245-3418 in the C-terminal domain of the protein. Antigen unmasking techniques were employed, including pretreatment in a 6.0 pH citrate buffer microwaved for 30 min. A secondary antibody was then applied and the enzymatic reaction completed using a streptavidin-biotin detection kit (Dako, CA) for 5 min. The sections were counterstained with hematoxylin and embedded in 70% glycerol aqueous solution. MCF7 cell lines were used as positive controls for BRCA2 staining.
The four study pathologists (RF, MF, JMM and HI) scored the C-terminal and N-terminal BRCA2 staining magnitude and location for each core, blinded to the outcome results. The staining magnitude was measured using staining intensity on a scale from 0 to 4 and percent of cells positive for the stain on a scale from 0 to 100%.
Statistical methods
To calculate an overall BRCA2 expression score, the average of the staining intensity (scale from 0 to 4) and percent of positive cells across the cores were multiplied together for each patient. We defined a patient as having positive staining in a specific cellular location if he had at least one core with any staining in that location.
The overall expression score as well as indicators of a positive (+) or negative (−) staining in the nucleus, membrane (mem), cytoplasm (cyt) and combinations thereof, were evaluated for association with lethal prostate cancer within 5 years. Logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI), adjusted for known risk factors including age at diagnosis (continuous), year of diagnosis (1977-89, 1990-92, 1993-98) and Gleason score (2-6, 3+4, 4+3, [8] [9] [10] . The distributions of expression scores were compared using the two-sample Wilcoxon rank-sum (Mann-Whitney) test, the chi-square test and Fisher's exact test were used to compare proportions. Non-parametric tests for trends across ordered groups were done according to Cuzick (17) .
All statistical tests were two-sided and evaluated at the significance level of 0.05. Statistical analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC) and STATA 10.0 for Windows.
Results
Median follow-up time for the 71 cases was 2.9 years (range 0.30-4.9 years). For the 165 controls, the median follow-up time was 11.6 years (range 7.3-22.3 years). BRCA2 protein staining for each cellular location is depicted in Figure 1 . Of the 236 patients included in the study, 87% had C-terminal staining in at least one core and 95% had N-terminal staining. Nuclear C-and N-terminal staining was present for 17 and 21% of the patients, respectively, and membranous C-and N-terminal staining was
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confidence interval OR odds ratio TMA tissue microarray detected for 71 and 69% of the patients, respectively. When considering cytoplasmic staining, the results differed according to which antibody was used; C-terminal staining was detected for 53% of patients and N-terminal staining for 93% of patients. Concordance between C-and N-terminal staining was 78, 86 and 58% in the nucleus, cell membrane and cytoplasm, respectively. Clinical characteristics for cases and controls are shown in Table 1 . The cases were older and had more advanced disease, as indicated by a higher proportion with T1b tumor stage and 8-10 Gleason scores, than among indolent controls.
Overall BRCA2 expression
The median C-terminal BRCA2 expression score followed the hypothesized direction of effect, with a higher median expression score of 64.1 in the indolent controls and the lower median score of 37.8 in the cases (P = 0.06) ( Table 1 ). The N-terminal BRCA2 expression score was also lower in cases than controls (P = 0.05). As shown in Table 2 , a high overall N-terminal expression score was associated with a reduced risk of lethal prostate cancer within 5 years, after adjusting for age, year of diagnosis and Gleason score in a logistic regression model (OR = 0.45, 95% CI = 0.22-0.93). A significant association was not present for the expression score based on C-terminal staining. Gleason score was not associated with overall staining magnitude as measured by the expression score (data not shown).
Nuclear staining
For each of the C-and N-terminal antibodies, nuclear BRCA2 staining was present in between 16 and 22% of patients (Table 1) and did not differ significantly between cases and controls (P = 0.32 and 0.66 for C-and N-terminal antibody staining, respectively). Nuclear staining was neither associated with lethality in logistic regression models (Table 2) nor with Gleason score (data not shown). 
Cytoplasmic staining
Detection of cytoplasmic C-terminal staining was associated with an increased risk of lethal cancer. The percent of patients with positive staining was 46.7% in the indolent controls and 67.6% in the rapidly fatal cases (P = 0.003) ( Table 1) . This association was not observed for the N-terminal antibody, which was positive for over 90% of patients in both outcome groups. Similarly, in logistic regression models a positive cytoplasmic C-terminal staining was associated with rapid lethality (OR = 3.61, 95% CI = 1.61-8.07, P = 0.002) but no association was seen for the N-terminal antibody (Table 2) . Lower Gleason scores were more prominent among patients with no staining by C-terminal antibody, compared to positive staining (P = 0.004). No association with Gleason score was observed for the N-terminal antibody (Table 3) .
Membranous staining
For each of the two antibodies, staining at the cell membrane was present in a lower percentage of cases (C-terminal: 57.7%; N-terminal: 56.3%) as compared to indolent controls (C-terminal: 76.4%; N-terminal: 74.5%). The comparison between cases and controls was statistically significant with respective P values of 0.004 (C-terminal) and 0.006 (N-terminal) ( Table 1 ). The adjusted ORs were 0.47 (95% CI = 0.21-1.04, P = 0.06) for C-terminal and 0.41 (95% CI = 0.18-0.91, P = 0.03) for N-terminal staining (Table 2) . A negative membranous staining showed a statistically significant association with higher Gleason scores (P = 0.006 for each of the two antibodies) ( Table 3) .
Combined cytoplasmic and membranous staining
We finally considered combined staining groups (Table 2 ). In the adjusted logistic regression model, comparing with individuals who had positive cytoplasmic staining (cyt+) and negative membranous staining (mem-) for the C-terminal, the risk of lethal cancer within 5 years was lowest among patients who had the opposite combination, i.e. negative cytoplasmic staining and positive membranous staining (cyt−/mem+) (OR = 0.13, 95% CI = 0.04-0.49, P = 0.002). This association was not observed for the N-terminal antibody, which was likely because over 90% patients had positive cytoplasmic staining in the case-control groups. Among individuals who, according to C-terminal staining, had the unfavorable combination (cyt+/mem−) 10% of tumors had the lowest Gleason score (2-6) and 37% the highest (8-10) (Table 3) and for the opposite staining combination (cyt−/mem+) the proportions were significantly different; 41% had Gleason score 2-6 and 14% had score 8-10 (P < 0.001) (Figure 2 ).
Discussion
In the population-based Swedish Watchful Waiting Cohort, the subcellular location of BRCA2 protein in cancer cells was predictive of lethal prostate cancer within 5 years of diagnosis after adjustment for Gleason score, and was also separately associated with Gleason score at diagnosis. The original hypothesis of this study was that lower expression of the BRCA2 protein in prostate cancer cells would be associated with an increased risk of lethal prostate cancer. However, the results indicate a more complex pattern.
At the cell membrane, C-and N-terminal staining was positive for 71 and 69% of patients, respectively. There was high correlation between the two antibodies, and for each of them a positive status was associated with only half the risk of lethal cancer as compared with a negative status, in the logistic regression. For both antibodies, membranous staining was also independently associated with significantly lower Gleason scores. Together, these results indicate that BRCA2 protein expression at the membrane in prostate cancer cells may have biological significance. It has recently been suggested that the BRCA1 protein may have a role in the motility and migration of cancer cells, where it was found to colocalize with ERM proteins that act as cross-linkers between the cell membrane and the underlying F-actin cytoskeleton (12) . It could be speculated that BRCA2 might have a role similar to BRCA1 in the cell membrane, since mutations in the BRCA1 and BRCA2 genes predispose individuals to cancers of the breast and ovaries and both proteins have a function in the nucleus relating to the maintenance of genomic stability.
We detected nuclear expression in around 20% of prostate cancer patients for each of the N-and C-terminal antibodies. Nuclear expression was not associated with Gleason score or lethality. A previous study using an antibody against amino acids 2301-2320 reported nuclear staining in 22% of prostate cancer cells and no expression in normal prostate cells (18) . A more recent study based on the same C-terminal antibody as used in the current study similarly found a 23% level of nuclear expression in prostate cancer cells, contrasting with a much higher level of nuclear expression (80%) in normal prostate cells (13) . In the cytoplasm, the agreement between N-and C-terminal staining was considerably lower than for membrane and nuclear expression. Cytoplasmic staining was positive for 93% of the patients using the N-terminal antibody and positive for only 53% of the patients using the C-terminal antibody. C-terminal staining, but not N-terminal staining, in the cytoplasm was associated with somewhat higher Gleason scores and a significantly increased risk of lethal cancer. This disagreement might indicate that some patients have a split or truncated protein in the cytoplasm.
Cytoplasmic accumulation of BRCA2 has been observed in association with truncations at the C-terminal and nuclear signals are located within the final 156 residues of the protein (11) . A mis-sense mutation at D2723H in BRCA2 is associated with aberrant cellular localization (19) and this cancer-associated mutation disturbs protein-protein interactions that normally mask nuclear exclusion signals for the proteins BRCA2 and RAD51 (8) . Finally, although BRCA2 has hitherto only been considered to be a nuclear protein, there is reason to believe that it may be found also in the cytoplasm in connection with its role in the control of centrosome localization by its interaction with cytoskeletal proteins (20) .
In a study where the magnitude of expression according to intracellular location was reported for the beta-catenin protein, which is important for the regulation of cell adhesion and proliferation, a shift in expression from the membrane to the cytoplasm was associated with a worse breast cancer outcome (21) . A similar mechanism may be at work in the current study, where negative membranous and positive cytoplasmic BRCA2 staining was associated with less favorable prognoses and Gleason scores as compared with positive membranous and negative cytoplasmic staining.
In accordance with the original hypothesis, the overall expression level was negatively associated with lethal and rapidly lethal prostate cancer within 5 years of diagnosis when using N-terminal staining. However, this parameter alone was not very informative. The observed association may be driven by expression in the cell membrane, which was negatively associated with lethality.
This study is limited by the fact that expression magnitude was not measured based on intracellular location, which restricts our ability to interpret our expression level results and to extend the staining location analyses. As another limitation, the patients were not assessed for inherited BRCA2 mutations, which are known to be associated with reduced prostate cancer survival (3, 4) . However, as the prevalence of BRCA2 mutations among unselected prostate cancer patients is around 2% (3,4) , a maximum of five mutation carriers would be expected among the 236 patients in the current study and their potential presence is not likely to explain the current findings. Since four different pathologists scored the magnitude and location of BRCA2 staining, it is possible that scoring variation across pathologists introduced some measurement error. Further, this study included only patients diagnosed incidentally by TURP, and it would be of interest in further studies to explore BRCA2 protein expression using prostate specimens taken by biopsy.
Strengths of the study include a large number of participants with BRCA2 protein expression information, as well as the novel information collected on both the magnitude and intracellular location of BRCA2 expression in tissue sampled at diagnosis. The patients were selected from a general population of prostate cancer patients with low stage tumors, which also reduces the potential confounding by genetic factors. The unique personal identification numbers of the Swedish patients included in the study were used to track all contact with the health care system, so this study is based on relatively complete follow-up.
While prior studies have shown an association between inherited BRCA2 mutations and prostate cancer progression, the present study represents the first demonstrated association between BRCA2 protein expression and progression in a group of newly diagnosed men with unknown mutation status. Those results need confirmation, but they suggest that BRCA2 protein expression assessment based on subcellular location could potentially improve the prediction of prostate cancer prognosis. Further research is warranted to study associations with staining intensity at each subcellular location and to assess whether the association varies by Gleason grade. Furthermore, as the BRCA2 protein is known to be a nuclear protein it is of interest that nuclear expression was present in less than 20% of the prostate cancer specimens. BRCA2 protein expression at the cellular membrane and its association with progression need to be further investigated.
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